• 中信银行收购阿尔金银行后新股东“首聚” 2019-07-22
  • 广州南沙区以物联网创新应用探索消防大数据管理模式 2019-07-16
  • 呼和浩特市全面停止大青山脉矿山勘查开发建设活动 2019-07-16
  • 特朗普所言克里米亚是俄罗斯的和出尔反尔对中国500亿美元商品宣布开征巨额关税,此两点已形成了鲜明的对比,从而充分的暴露了美国真实的战略意图。(原创首发) 2019-07-16
  • 小鸣单车进入破产程序 押金未退用户可申报债权 2019-07-14
  • 国地税合并惠及当下立足长远 2019-07-14
  • 中日韩三国记者“环保行”联合采访——日本 2019-07-13
  • 新疆优秀出版物上网工程 2019-07-13
  • 绘就美丽西藏壮美画卷 2019-07-06
  • 长城新媒体集团有限公司 采访设备采购公告 2019-06-30
  • 最低工资标准相关新闻 2019-06-30
  • 深秋烟雾偎婺源文章中国国家地理网 2019-06-27
  • 抓住历史机遇发展数字经济 2019-06-24
  • 美国代表历史与现在,中国代表现在与未来。美国产品退出中国市场,几乎等于退出亚洲市场 2019-06-19
  • 杜克当选新一任哥伦比亚总统 2019-06-18
  • About Us

    Shanghai Shyndec Pharmaceutical Co.,Ltd,

    Shanghai Shyndec Pharmaceutical Co.,Ltd, which was established in 1996, is a high-tech enterprise in the pharmaceutical industry which is specialized in manufacturing new drug preparation products and founded by academician of Chinese Academy of Engineering. It was listed on Shanghai stock exchange on June 16, 2004 (stock code: 600420, stock abbreviation:现代制药). In April 2010, it entered China National Pharmaceutical Group Corporation(SINOPHARM).

    In 2016-2017, according to the integration strategy ofSINOPHARM, Shanghai Shyndec Pharmaceutical Co.,Ltd positioned itself as a pharmaceutical industry platform of SINOPHARM, have actively promoted major asset restructuring matters. The main business of the "new Shyndec " wholly-owned or holding subsidiary after the reorganization has achieved nearly 10 billion level of revenue, total profit has exceeded 1 billion yuan, and the number of enterprise members has reached 30, among which 17 are secondary enterprises, 13 are tertiary and four-level enterprises.

    After the reorganization, the "New Shyndec" has integrated into many high-quality industrial product lines and enterprise assets of China National Pharmaceutical Group to create a more centralized resource allocation and a clearer main business market. Focusing on the "anti-infection, cardiovascular and cerebrovascular, anti-tumor, leptin drugs, metabolism and endocrine" five areas then has formed and strengthened the "5 + X" industrial chain system with the modern characteristics and core competitiveness of Chinese medicine. The product structure of the company will be richer, the R&D strength will be further strengthened, and the market position of the enterprise has been improved by leaps and bounds.

    For a year, Shanghai Shyndec Pharmaceutical Co.,Ltd has been guided by "big reorganization, large integration, great amalgamation and fully development". Through the three main paths of " big reorganization of institutional framework, great amalgamation of ideology and culture, great integration of personnel assets" to achieve the development goal of large-scale integration of the group chemical pharmaceutical industry and strive to create a platform of chemical pharmaceutical industry under the guidance of innovation.

    • Stock Code

      600420

    • Stock Abbreviation

      现代制药

    • Company Address:

      Building 1, No. 1320, west Beijing road, Shanghai

    Organizational Structure

  • 中信银行收购阿尔金银行后新股东“首聚” 2019-07-22
  • 广州南沙区以物联网创新应用探索消防大数据管理模式 2019-07-16
  • 呼和浩特市全面停止大青山脉矿山勘查开发建设活动 2019-07-16
  • 特朗普所言克里米亚是俄罗斯的和出尔反尔对中国500亿美元商品宣布开征巨额关税,此两点已形成了鲜明的对比,从而充分的暴露了美国真实的战略意图。(原创首发) 2019-07-16
  • 小鸣单车进入破产程序 押金未退用户可申报债权 2019-07-14
  • 国地税合并惠及当下立足长远 2019-07-14
  • 中日韩三国记者“环保行”联合采访——日本 2019-07-13
  • 新疆优秀出版物上网工程 2019-07-13
  • 绘就美丽西藏壮美画卷 2019-07-06
  • 长城新媒体集团有限公司 采访设备采购公告 2019-06-30
  • 最低工资标准相关新闻 2019-06-30
  • 深秋烟雾偎婺源文章中国国家地理网 2019-06-27
  • 抓住历史机遇发展数字经济 2019-06-24
  • 美国代表历史与现在,中国代表现在与未来。美国产品退出中国市场,几乎等于退出亚洲市场 2019-06-19
  • 杜克当选新一任哥伦比亚总统 2019-06-18
  • 萨索洛切沃 暗恋客服 排列三走势图 红利扑克5手闯关 巴黎圣日耳曼vs甘冈 时时彩大神预测在线 街头乐队送彩金 大亨小传游戏 打贵州麻将技巧 国王杯皇马莱万特